|
1 |
A Biomed company aiming to leverage proprietary computational systems including AI to accelerate development of novel drug alternatives to life threatening diseases like cancer, bacterial infections and muscular dystrophy. |
AI & Drug Development |
USA |
$20m |
IND |
Request
|
|
2 |
A Biomed company providing specialised rehabilitation services to treat patients suffering from drug addiction and opioid dependence with clinics using therapies from a specialised drug. The company is focused on creating a diverse real estate portfolio with healthcare and detox related assets whose sole purpose are to establish turn-key addiction recovery facilities. |
Addiction |
Canada |
$5m |
Pre revenue |
Request
|
|
3 |
A Biomed company that is developing a novel therapeutic class of medicines that use the body's natural immune response to decrease inflammation and stimulate repair mechanisms, thereby repairing the damage caused by disease and slowing aging. |
Aging |
USA |
$50m |
Phase 3 |
Request
|
|
4 |
A Biomed company in its commercial stages with products designed to empower people to stay younger longer with DNA analysing technology that helps patients understand their telomere length and better care for their cells with the provided knowledge, encouragement and goal setting. |
Aging |
USA |
$15-20m |
Commercial stage |
Request
|
|
5 |
A Biotech company with a mission to apply AI technology to accelerate drug discovery in order to make the process quicker and more cost-efficient. |
AI & Drug Development |
China |
$10m |
Pre-A |
Request
|
|
6 |
A Biopharmaceutical company developing new drugs faster and cheaper with lower risk based on biological big data-based and AI-driven drug development. |
AI & Drug Development |
USA |
$6.5m |
Revenue generating & early hit to lead stage |
Request
|
|
7 |
A Pharmaceuticals company developing and commercializing anti-inflammatory therapeutics, with the company?s lead program around the proprietary target molecule TIRC7, promising a significant leap in the treatment of autoimmune diseases and transplanted organ rejection |
Anti-inflammatory Therapeutics |
USA |
$15m |
Preclinical |
Request
|
|
8 |
A Biopharmaceutical company developing a pro-resolving drug focused on treating Cystic Fibrosis through anti-inflammatory mechanisms involving docosahexaenoic acid, terminating inflammation without inducing immune suppression.. |
Anti-inflammatory Therapeutics |
Canada |
$4m |
Phase 2 |
Request
|
|
9 |
A Biomed company that is developing the first specific treatment for anti-phospholipid syndrome, to help prevent thrombus formation and fetal loss in patients suffering from the disease. |
Antiphospholipid Syndrome |
Norway |
$2.6m |
Preclinical |
Request
|
|
10 |
A Medical Software company that has built an enterprise software platform that links biological design with automation, testing and machine learning with examples of use being multi-year crop protection biomolecule design/build/test project. |
Biology Software |
USA |
$8m |
Revenue generating |
Request
|
|
11 |
A Biotech company focused on the development of a phase 3 angiogenic gene therapy product candidate for the treatment of refractory angina and cardiac syndrome X, among other indications. |
Cardiovascular |
USA |
$5m |
Phase 3 |
Request
|
|
12 |
A Medical Device company that is producing an ECMO (extra corporeal membrane oxygenation) machine which is easily transportable and designed to provide better outcomes for patients and less time in the intensive care unit. |
Cardiovascular |
Canada |
$5m |
Awaiting FDA approval |
Request
|
|
13 |
A Biotech company that has developed a nano-therapeutic delivery system containing conjugated rapamycin that can target unseen, unstable cardiovascular atherosclerotic plaques directly at the source of the problem. |
Cardiovascular |
USA |
$5.67m |
Pre-IND |
Request
|
|
14 |
A revenue generating Medical Device company producing the latest treatment option using radiofrequency ablation (laser), to treat patients with venous disease and varicose veins/swelling/aching legs/lower limb ulcers. |
Cardiovascular (Venous Disease) |
USA |
$10-$12m |
Revenue generating |
Request
|
|
15 |
A Biomed company producing antiplatelet therapy for Clopidogrel-resistant heart attack and stroke patients which has more efficacy and less bleeding risk. |
Cardiovascular and Metabolic |
USA |
$8m |
Phase 1 |
Request
|
|
16 |
A Product Development company focused on biomaterial innovations for the dental market, seeking to commercialise the dental product portfolio for socket extractions, implant packing, ridge augmentation and sinus lift. |
Dentistry |
USA |
$5.5m |
Preclinical |
Request
|
|
17 |
A Biotech company focused on altering the delivery pathways for well-known drugs, currently administered only by injections, to non-invasive (oral or sublingual) routes. |
Drug Delivery |
USA |
$1-2m |
Currently licensing |
Request
|
|
18 |
A Biotech company developing a wireless remote controlled drug delivery system, providing effective and targeted drug delivery via an ingestible capsule. |
Drug Delivery |
USA |
$3m |
Preclinical |
Request
|
|
19 |
A Drug Development company currently developing three promising drugs including radioprotection drugs for prevention of oral mucositis in head and neck cancer currently in phase 2, IBS-D drugs with phase 2a complete and nocturia drugs also with phase 2a complete. |
Drug Development |
USA |
$40m |
Phase 2 |
Request
|
|
20 |
A Biopharmaceutical company focused on high-end generics and 505b2 new drugs currently building a portfolio of drugs to commercialise. |
Drug Development |
China |
$20m |
Revenue generating |
Request
|
